The compound directory

A dual incretin agonist combining GIP and GLP-1 receptor activity in a single molecule, associated with larger mean body-mass reductions than single-pathway GLP-1 agonists in comparative trials.

A long-acting GLP-1 receptor agonist and the most studied compound in the incretin-mimetic class, used as the reference point for newer dual and triple agonists.

A long-acting amylin receptor agonist studied both alone and in fixed-ratio combination with semaglutide (as CagriSema), targeting a signaling pathway distinct from the incretin hormones.

A dual agonist pairing GLP-1 with glucagon receptor activity, studied as a mechanistically distinct alternative to tirzepatide-style GIP/GLP-1 dual agonism, with a research emphasis on hepatic fat handling.

A triple-receptor agonist that layers glucagon receptor activity on top of GIP and GLP-1 signaling, currently the most mechanistically aggressive compound in active late-stage trials for this class.

A small-molecule triple monoamine reuptake inhibitor studied for appetite suppression through a central nervous system pathway entirely separate from incretin receptor agonism, often researched alongside GLP-1 compounds as a mechanistically distinct comparator.

A modified fragment of the C-terminal region of human growth hormone, isolated to retain the lipolytic activity of full-length GH without its effect on growth or insulin resistance.

A synthetic analog of growth hormone-releasing hormone (GHRH), studied for its selective effect on visceral adipose tissue rather than overall body mass.

A commonly paired combination of a GHRH analog (CJC-1295) and a selective ghrelin-receptor agonist (Ipamorelin), used together to produce a synergistic GH pulse with minimal effect on cortisol or prolactin.

A small-molecule NNMT inhibitor, not a peptide. Included here because it is frequently studied alongside peptide-class weight-loss compounds and sourced through the same research channels.

A once-daily GLP-1 receptor agonist and the first incretin-mimetic to reach approval for chronic weight management, now used as the historical baseline against which longer-acting analogs are measured.

An oral, small-molecule GLP-1 receptor agonist rather than an injectable peptide, studied for whether a pill can reproduce the weight-loss effect of injectable incretin therapy without the manufacturing and cold-chain burden of a peptide.

A dual agonist pairing GLP-1 with glucagon receptor activity rather than GIP, studied as a mechanistically distinct alternative to tirzepatide-style incretin dual agonism.

A 29-amino-acid fragment of growth hormone-releasing hormone, shorter-acting than tesamorelin and used as a research comparator for how fragment length affects pituitary GH pulsatility.